Cell in Cells has a pipeline of organoid regenerative therapies for various diseases, including skin regeneration, cartilage regeneration, and angiogenesis. Its technology can mass-produce uniform organoids with a probability of over 95 percent.
Organoid therapeutics help regenerate human organ analogs by culturing cells in three dimensions and transplanting them into damaged parts. They are characterized by a higher engraftment rate and persistence than two-dimensional stem cell therapies.
To expand and upgrade its technology, the company is pushing to fuse organoids and artificial intelligence (AI) technology to automate production, establish standards and test methods, and develop solutions to optimize mass production.
| Contact Details | Seoul National University 207 Ho, 101 Daehak-ro, Jongno-gu, Seoul http://www.cellincells.com/02-740-8641 |
|---|
Their main modalities include SDR-Grafting, Recombinant Protein Fusion, CHIMPS Bispecific Antibodies, SHOCAP Bispecific Antibodies, and Bitargeting Receptor-Antibody Hybrid
